Survival Rate for Cancer Increases in Canada
Statistics show that Canadians are living longer after cancer:
"Canadians diagnosed with cancer are living longer and the survival rate for sufferers of a number of cancers, including leukemia, has increased dramatically, a Statistics Canada report released Wednesday showed.
After looking at the five-year relative survival ratio for patients, the federal agency reported the survival rate for Canadians diagnosed with any type of cancer between 2004 and 2006 was 62 per cent, a six per cent increase from data from 1992 to 1994.
“It’s particularly encouraging to see that there’s been an increase in survival for several types of cancer like leukemia, thyroid, liver and non-Hodgkin lymphoma. Those types of cancers have low survival rates traditionally,” said Prithwish De, an epidemiologist with the Canadian Cancer Society."
Read More: http://www.canada.com/health/Cancer+survival+rates+increase+Canada+Stats...
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
